Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer early ...

For women, ovarian cancer is one of the most feared of all diagnoses. Sneaking up silently, often with few symptoms, the ...

Colorectal cancer (CRC) is a major public health issue, with over 43,000 new cases and nearly 17,700 deaths annually in France. The overall survival rate is currently 63%. It is much higher for early ...

We knew we had something interesting with T3p, a single small RNA found in breast cancer but absent from normal tissue. After being described in 2018, this molecule took our team on a six-year journey ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj ...

After being described in 2018, researchers knew they had something interesting with T3p, a single small RNA found in breast ...

Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...

When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...

Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...